Key Insights

• CorMedix to hold its Annual General Meeting on 21st of November
• Total pay for CEO Joe Todisco includes US$617.0k salary
• The overall pay is comparable to the industry average
• CorMedix's total shareholder return over the past three years was 124% while its EPS was down 7.3% over the past three years

Performance at CorMedix Inc. (NASDAQ:CRMD) has been reasonably good and CEO Joe Todisco has done a decent job of steering the company in the right direction. As shareholders go into the upcoming AGM on 21st of November, CEO compensation will probably not be their focus, but rather the steps management will take to continue the growth momentum. Based on our analysis of the data below, we think CEO compensation seems reasonable for now.

How Does Total Compensation For Joe Todisco Compare With Other Companies In The Industry?

According to our data, CorMedix Inc. has a market capitalization of US$708m, and paid its CEO total annual compensation worth US$2.5m over the year to December 2023. That's a notable decrease of 15% on last year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$617k.

For comparison, other companies in the American Pharmaceuticals industry with market capitalizations ranging between US$400m and US$1.6b had a median total CEO compensation of US$2.9m. This suggests that CorMedix remunerates its CEO largely in line with the industry average. Moreover, Joe Todisco also holds US$2.1m worth of CorMedix stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

On an industry level, around 28% of total compensation represents salary and 72% is other remuneration. CorMedix is largely mirroring the industry average when it comes to the share a salary enjoys in overall compensation. If non-salary compensation dominates total pay, it's an indicator that the executive's salary is tied to company performance.

A Look at CorMedix Inc.'s Growth Numbers

Over the last three years, CorMedix Inc. has shrunk its earnings per share by 7.3% per year. Its revenue is up 41,184% over the last year.

Investors would be a bit wary of companies that have lower EPS But on the other hand, revenue growth is strong, suggesting a brighter future. It's hard to reach a conclusion about business performance right now. This may be one to watch. Moving away from current form for a second, it could be important to check this free visual depiction of what analysts expect for the future.

Has CorMedix Inc. Been A Good Investment?

We think that the total shareholder return of 124%, over three years, would leave most CorMedix Inc. shareholders smiling. As a result, some may believe the CEO should be paid more than is normal for companies of similar size.

In Summary...

Some shareholders will be pleased by the relatively good results, however, the results could still be improved. Despite robust revenue growth, until EPS growth improves, shareholders may be hesitant to increase CEO pay by too much.

While CEO pay is an important factor to be aware of, there are other areas that investors should be mindful of as well. We did our research and spotted 3 warning signs for CorMedix that investors should look into moving forward.

Switching gears from CorMedix, if you're hunting for a pristine balance sheet and premium returns, this free list of high return, low debt companies is a great place to look.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.